Tianjin TEDA Biomedical Engineering : ANNOUNCEMENT ON HALF-YEARLY RESULTS FOR 2017

天津泰達生物醫學工程股份有限公司

Tianjin TEDA Biomedical Engineering Company Limited

(a joint stock company incorporated in the People's Republic of China with limited liability)

(Stock code: 8189) ANNOUNCEMENT ON HALF-YEARLY RESULTS FOR 2017 CHARACTERISTICS OF THE GROWTH ENTERPRISE MARKET ("GEM") OF THE STOCK EXCHANGE OF HONG KONG LIMITED (THE "STOCK EXCHANGE") GEM has been positioned as a market designed to accommodate companies to which a higher investment risk may be attached than other companies listed on the Stock Exchange. Prospective investors should be aware of the potential risks of investing in such companies and should make the decision to invest only after due and careful consideration. The greater risk profile and other characteristics of GEM mean that it is a market more suited to professional and other sophisticated investors. Given the emerging nature of companies listed on GEM, there is a risk that securities traded on GEM may be more susceptible to high market volatility than securities traded on the Main Board and no assurance is given that there will be a liquid market in the securities traded on GEM.

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

The information set out in this announcement, for which the directors of Tianjin TEDA Biomedical Engineering Company Limited ("the Company") collectively and individually accept full responsibility, is given in compliance with the Rules Governing the Listing of Securities on the GEM of The Stock Exchange for the purpose of giving data with regard to the Company. The directors of the Company, having made all reasonable enquiries, confirm that, to the best of their knowledge and belief, the information contained in this announcement is accurate and complete in all material respects and not misleading or deceptive, and there are no other matters the omission of which would make this announcement or any statement herein misleading.

HIGHLIGHTS

• Consolidated turnover of the Group for the six months ended 30 June 2017 amounted to RMB157,551,363, representing a decrease of 24.77% as compared to the same period of last year (30 June 2016: RMB209,435,809).

• Consolidated gross profit of the Group for the six months ended 30 June 2017 amounted to RMB21,873,195, representing a decrease of 48.74% as compared to the same period of last year (30 June 2016: RMB42,674,864).

• Loss attributable to the equity owners of the Company for the six months ended 30 June 2017 was RMB5,805,526, the company's equity owners should make a profit of 8,740,566 in the same period last year; the loss per share of the Company was RMB0.358 cents as compared to earnings per share of RMB0.548 cents of the same period of last year.

• The Board does not recommend the payment of dividend for the six months ended 30 June 2017.

HALF-YEARLY RESULTS (UNAUDITED)

The board of directors (the "Board") of Tianjin TEDA Biomedical Engineering Company Limited (the"Company") is pleased to announce the unaudited half-yearly results of the Company and its subsidiaries (hereafter collectively referred to as the "Group") for the six months ended 30 June 2017, together with the comparative figures of the corresponding period in 2016 as follows:

CONDENSED CONSOLIDATED PROFIT AND LOSS ACCOUNT (Unaudited) (Unaudited)

2017	2016	2017	2016
Notes	RMB	RMB	RMB	RMB

For the six months ended 30 June For the three months ended 30 June

Continuing operation Revenue	2	157,551,363	209,435,809	90,376,770	121,018,846
Cost of sales	(135,678,168)	(166,760,945)	(77,816,419)	(96,118,965)
Gross profit	21,873,195	42,674,864	12,560,351	24,899,881
Other expenses and net loss/Income	(182,077)	(3,162,341)	216,746	(832,598)
Selling and distribution costs	(6,461,881)	(8,564,906)	(3,272,160)	(4,065,144)
R&D and administrative expenses	(18,445,059)	(18,961,631)	(10,450,925)	(10,797,835)
Finance costs	3	(1,812,667)	(1,784,017)	(983,491)	(825,337)
(Loss)/Profit before taxation	(5,028,489)	10,201,969	(1,929,479)	8,378,967
Income tax	5	(691,200)	(1,620,370)	(351,662)	(1,266,086)
(Loss)/Profit and comprehensive income
for the period from continuing operation	(5,719,689)	8,581,599	(2,281,141)	7,112,881

Discontinued operation

Loss for the period from discontinued

operation - - - -

(Loss)/Profit and comprehensive income for the period (5,719,689) 8,581,599 (2,281,141) 7,112,881 (Unaudited) (Unaudited)

2017	2016	2017	2016
Notes	RMB	RMB	RMB	RMB

For the six months ended 30 June For the three months ended 30 June Attributable to:

Owners of the Company

• (Loss)/Profit for the period from

  continuing operation (5,805,526) 8,740,566 (2,866,388) 6,502,247

• Loss for the period from

  discontinued operation - - - -

  Non-controlling interests

• Profit/(Loss) for the period from

  continuing operation 85,837 (158,967) 585,247 610,634

• Loss for the period from

discontinued operation - - - -

Profit/(Loss) for the period attributable to

non-controlling interests 85,837 (158,967) 585,247 610,634

(Loss)/Earnings per share-Basic (RMB) 6

From continuing and

discontinued operation (0.358) cents 0.548 cents (0.177) cents 0.408 cents

From continuing operation (0.358) cents 0.548 cents (0.177) cents 0.408 cents